Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 9/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24265338 | 0.89 | ACSS2 (0.46) | GLP1RPPARGACSS2 | |
| SCHEMBL30740718 | 0.89 | ACSS2 (0.46) | GLP1RPPARGACSS2 | |
| SCHEMBL22392102 | 0.86 | GLP1R (0.44) | GLP1RPPARGAGTR1AGTR2ACSS2 | |
| SCHEMBL3059937 | 0.82 | NTRK1 (0.47) | PPARGAGTR1AGTR2NTRK1NTRK2 | |
| SCHEMBL26541207 | 0.81 | GLP1R (0.42) | GLP1RPPARGAGTR1AGTR2NTRK1 | |
| SCHEMBL29945993 | 0.80 | ACSS2 (0.41) | GLP1RACSS2 | |
| SCHEMBL30740795 | 0.80 | ACSS2 (0.46) | GLP1RPPARGACSS2 | |
| SCHEMBL29826815 | 0.80 | ACSS2 (0.46) | GLP1RPPARGACSS2 | |
| SCHEMBL25365576 | 0.79 | NPC1 (0.42) | MEN1KMT2A | |
| SCHEMBL25465754 | 0.79 | PDE10A (0.39) | PPARGAGTR1AGTR2NTRK1NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885PPARG 87/4885AGTR1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.